Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Other solid neoplasm 1Genitourinary 1

Conditions

Recurrence 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Acute Disease 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × AGRO 100 × Other hematologic neoplasm × Clear all
NCT01034410 2011-02-02

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Antisoma Research

Phase 2 Terminated
90 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00512083 2009-09-25

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Antisoma Research

Phase 2 Completed
70 enrolled
Other hematologic neoplasm

Acute Disease, Leukemia, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡